# Biological E. expands vaccine facility in Hyderabad with $50M DFC financing

Biological E. Limited finalized a $50 million financing arrangement with the U.S. International Development Finance Corporation to expand its COVID-19 vaccine manufacturing facility in Hyderabad, India. The expansion aims to support production of more than one billion vaccine doses by end of 2022.

- Type: Expansion
- Announced: 2021-10-25
- Where: Hyderabad, India, India
- Value: $50.0M
- Starts operating: 2022
- Status: under construction
- Capacity: more than one billion vaccine doses by end of 2022
- Products: COVID-19 vaccines
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Biological E. Limited](https://endata.com/companies/21997.md)
- [U.S. International Development Finance Corporation](https://endata.com/companies/58675.md) (investor)

## Sources

- [dfc.gov](https://www.dfc.gov/media/press-releases/dfc-and-biological-e-limited-finalize-financing-arrangement-expand-covid-19), 2021-10-25: "DFC's partnership with Biological E will support capacity for production of more than one billion vaccine doses by the end of 2022 for India and for developing countries around the world."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.